| Similar Articles |
|---|
 |
The Motley Fool
February 14, 2011
Brian Orelli |
This Biotech Is Heating Up Biosante Pharmaceuticals was up more than 9% at one point today after the company said the independent Data Monitoring Committee believed Biosante's female sexual dysfunction drug, LibiGel, was safe enough to allow the trial to continue.   |
The Motley Fool
July 28, 2011
Brian Orelli |
But, But, But, I Thought You Were for Sale? BioSante raises cash -- guess it's not on the market. |
The Motley Fool
December 15, 2011
Brian Orelli |
BioSante Shares Crushed by Placebo Effect BioSante's LibiGel efficacy is not deemed statistically significant. |
The Motley Fool
December 14, 2011
David Williamson |
BioSante Investors: It Was Nice While It Lasted Libigel loses to placebo in two studies, shares down 75% after hours. |
The Motley Fool
January 29, 2008
Brian Lawler |
BioSante's Gamble Against Generics BioSante releases more information on the pivotal studies for its lead drug. |
The Motley Fool
December 15, 2011
Anders Bylund |
BioSante Pharmaceuticals' Shares Died: What You Need to Know Is this meaningful, or just another movement for BioSante Pharmaceuticals? |
The Motley Fool
August 31, 2011
Brian Orelli |
3 Biotechs Ready to Move Here are three biotechs with upcoming events that could drive their value higher: Exelixis... BioSante Pharmaceuticals... Amylin Pharmaceuticals... |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
December 27, 2010
Brian D. Pacampara |
BioSante Pharmaceuticals Shares Popped: What You Need to Know Shares of BioSante Pharmaceuticals, which develops products for female sexual health and oncology, soared a staggering 28% in intraday trading on extraordinarily high volume. |
The Motley Fool
October 14, 2011
Sean Williams |
7 FDA Decisions You Can't Afford to Ignore in Q4 These stocks are bound to move as the FDA weighs in on their prospective drugs in Q4: Bristol-Myers... BioSante... Teva... Regeneron... Transcept... Incyte... Antares Pharma... |
The Motley Fool
May 14, 2007
Brian Lawler |
Biosante's Lame Deal Last week, shares of the drugmaker were up 8% after the company announced that it had signed a drug development deal with a tiny European pharma, Pantarhei. |
The Motley Fool
December 15, 2011
David Williamson |
1 Massive Biotech Bloodbath Trial results and FDA panels ruled the health-care sector today. |
The Motley Fool
June 23, 2010
Kris Eddy |
Drugmakers Finally Recognize the Next Big Opportunity Drug companies seem to be increasing efforts to address female health problems. |
The Motley Fool
December 21, 2011
Brian Orelli |
Knocked Down? Not for Long! Last week shares of Antares Pharma got knocked down after BioSante Pharmaceuticals' LibiGel didn't live up to expectations. |
The Motley Fool
January 12, 2011
Brian Orelli |
Drugmaker Math: 4 Halves Beat 2 Wholes Eli Lilly and Boehringer Ingelheim hook up. |
The Motley Fool
October 31, 2006
Brian Lawler |
A Look Inside the Biotech Haunted House Even after being warned of the risks, if you're still brave enough to come inside the biotech haunted house, realize that there are surprises. For example, the FDA will spook investors with calls for more clinical trials on drugs that appear to be a lock for approval. |
The Motley Fool
November 16, 2011
David Williamson |
3 Biotechs Beating the Market The daily health-care news investors need to read. |
The Motley Fool
July 22, 2011
Brian Orelli |
That's All the Melanoma Market Is Worth? BioSante licenses out its melanoma vaccine for $100,000. |
The Motley Fool
November 29, 2011
Brian Orelli |
Every Biotech Is for Sale It just depends on the right price. |
CFO
October 1, 2009
Sarah Johnson |
Buying Cash That was one CFO's solution for keeping his small company afloat as it waits for regulatory approval of its product and continues to burn through funds. |
The Motley Fool
July 29, 2011
Brian Orelli |
Merck's Making All the Right Long-Term Moves Job cuts, but they're not in research. |
